Drug intelligence / Profile preview

HBW-013

Development stage: Preclinical
Lead developer: Hyperway Pharmaceutical
Modality: Small Molecules

Overview

HBW-013 is a small molecule oncology candidate developed by Hyperway Pharmaceutical. It is intended for the treatment of tumors and cancers. As of the latest pipeline updates, the asset has been out-licensed to an undisclosed partner for further development. Detailed information regarding its specific biological target or mechanism of action has not been publicly released by the developer.

Beyond the preview

Go deeper on HBW-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBW-013.

Explore the full profile